Project Grant R43CA298595
Award Date 9/16/25
Completion Date 8/31/26
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award of $443,564 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to develop a novel cancer vaccination platform using engineered skin commensal bacteria. The primary objective is to leverage a prevalent skin bacterium, Staphylococcus epidermidis, to stimulate tumor-specific T cell immunity and enhance cancer immunotherapy. The research aims to overcome barriers in genetic engineering of clinically relevant skin...
- The National Cancer Institute (NCI) awarded a $306,871 Project Grant to Vivere Oncotherapies, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to advance the development of their OV-151 oncolytic virotherapy product for the treatment of colorectal cancer. The project aims to: 1) characterize the delivery properties of the OV-151 clinical vector to tumors, 2) optimize the therapeutic cargo delivered by the vector, and 3) develop an inducible promoter to enhance...
- This federal Project Grant award of $222,998.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for engineering endogenous immune cells to express chimeric antigen receptors (CARs). The goal is to enable these engineered immune cells, including T cells, NK cells, and macrophages, to mediate potent killing of ovarian cancer cells. This...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $122,577 to Trustees of Boston University for the development and characterization of self-amplifying RNA lipid nanoparticles. The goal is to create a platform that can sustainably and simultaneously deliver multiple immunostimulatory and gene therapy payloads directly to solid tumors, which account for nearly 90% of adult cancers and are difficult to treat effectively. The project aims to...
- This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This federal Project Grant award, valued at $701,876.00, was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Weill Medical College of Cornell University. The award supports a systems-level approach to therapeutically targeting the STING protein in cancer. The project aims to develop a novel technology called SATseq that couples saturation mutagenesis with single-cell sequencing to map the structure-function landscape of the STING protein,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on the development of a novel injectable, imageable, and biocompatible hydrogel called XCSGel for the localized delivery of interleukin-12 (IL-12) immunotherapy to treat triple-negative breast cancer. The $398,039 award, effective September 18, 2025 through August 31, 2026, is being provided to Intra Therapeutics, LLC (UEI: WXS7GG74E6C9) to optimize the XCSGel-IL12 formulation prior...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...